About Us

Truvian Sciences was founded in 2015 by individuals with deep domain experience in healthcare, diagnostics, and consumer technology. Today, the team has expanded to include top scientists, engineers, and healthcare business leaders – each bringing specialized expertise to drive Truvian’s mission. Together, we are disrupting the blood testing industry to fulfill an unmet need, developing an automated benchtop FDA-cleared system that allows practitioners to deliver data to patients instantaneously on a secure and easy-to-use mobile platform.

Executive leadership

Jeff Hawkins

President and Chief Executive Officer

Katherine Atkinson

Chief Commercial Officer

Dena Marrinucci Ph.D.

Co-Founder and Senior Vice President of Corporate Development and Business Operations

Tho Tran

Vice President of Quality and Regulatory Affairs

For almost 20 years, Mr. Hawkins has held executive and management roles at the world’s leading healthcare companies. Specializing in the advancement of life-changing technologies, Mr. Hawkins joined Truvian Sciences as President and Chief Executive Officer in January 2018. Prior to Truvian, Mr. Hawkins was Vice President and General Manager of the Reproductive and Genetic Health Business at Illumina, Inc. Before Illumina, he served as Senior Vice President of Global Marketing and Program Management for GenMark Diagnostics. Previously, Mr. Hawkins held roles of increasing responsibility in business development for Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an M.B.A. from Keller Graduate School of Management.

Ms. Atkinson has more than 20 years of experience in the healthcare and life sciences industries, where she continuously creates customer-focused teams that achieve and exceed global commercial and sales goals. Prior to joining Truvian, Ms. Atkinson served as Epic Sciences’ Chief Commercial Officer, where she identified new strategic business opportunities and deepened existing strategic partnerships. Prior to Epic, Ms. Atkinson was Vice President of Business Development and Strategic partnerships at Edico Genome. Previously, she held roles of increasing responsibility at Illumina, including as Commercial Director of Global Channel Partners and Director, Global Channel Partners, LATAM & Inside Sales, Demand Generation and Product Care Teams. Ms. Atkinson’s previous experience also includes leadership roles at Fisher Scientific, Thermo Fisher and Beckman Coulter. She holds a B.A in Broadcast Journalism and Public Speaking from the University of Houston.

Dr. Marrinucci is a life science entrepreneur with a passion for introducing diagnostic technologies with potential to transform human health. She co-founded Truvian in late 2015 and leads research, operations, program management and strategic partnerships for the company. Prior to founding Truvian, Dr. Marrinucci founded Epic Sciences in 2008 and was the company’s Chief Scientific Officer. During her tenure at Epic, Dr. Marrinucci developed a novel circulating tumor cell technology and helped grow the company, overseeing its diagnostic collaborations with pharmaceutical companies and developing its clinical laboratory and assay development operations.

Dr. Marrinucci has been named to MIT Technology Review’s 35 Innovators Under 35, Foreign Policy’s Top 100 Leading Global Thinkers, and PharmaVoice 100’s Top Entrepreneurs. She was also named a 2016 Life Science Catalyst Award winner, has authored dozens of peer reviewed publications and is an inventor on 12 patents. Dr. Marrinucci also serves as an Advisor for Lynx Biosciences, a cancer diagnostic company. She holds a B.S. in Chemistry from the University of Vermont and a Ph.D. in Chemical Biology from The Scripps Research Institute.

Mr. Tran brings Truvian extensive experience in the medical device and diagnostics space, where he specializes in quality management and regulatory compliance. Throughout his career, he has orchestrated a variety of successful regulatory submissions and audits with the FDA, Health Canada, European Commission and other quality governing bodies worldwide. At Truvian, he is instrumental in the company’s plans toward securing FDA 510(k) clearance. Mr. Tran’s career in quality assurance includes his role as Director of Quality at GenMark Diagnostics, a leading provider of automated, multiplex molecular diagnostic testing systems. He has also held engineering roles with Life Technologies, Flextronics Medical, and Abbott Laboratories, where he was recognized with a management award for his leadership in implementing a new quality system and ProChain Project Management approach. Mr. Tran holds a B.S. from the School of Health Sciences at Excelsior College.

Jeff Hawkins

President and Chief Executive Officer

For almost 20 years, Mr. Hawkins has held executive and management roles at the world’s leading healthcare companies. Specializing in the advancement of life-changing technologies, Mr. Hawkins joined Truvian Sciences as President and Chief Executive Officer in January 2018. Prior to Truvian, Mr. Hawkins was Vice President and General Manager of the Reproductive and Genetic Health Business at Illumina, Inc. Before Illumina, he served as Senior Vice President of Global Marketing and Program Management for GenMark Diagnostics. Previously, Mr. Hawkins held roles of increasing responsibility in business development for Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an M.B.A. from Keller Graduate School of Management.

Katherine Atkinson

Chief Commercial Officer

Ms. Atkinson has more than 20 years of experience in the healthcare and life sciences industries, where she continuously creates customer-focused teams that achieve and exceed global commercial and sales goals. Prior to joining Truvian, Ms. Atkinson served as Epic Sciences’ Chief Commercial Officer, where she identified new strategic business opportunities and deepened existing strategic partnerships. Prior to Epic, Ms. Atkinson was Vice President of Business Development and Strategic partnerships at Edico Genome. Previously, she held roles of increasing responsibility at Illumina, including as Commercial Director of Global Channel Partners and Director, Global Channel Partners, LATAM & Inside Sales, Demand Generation and Product Care Teams. Ms. Atkinson’s previous experience also includes leadership roles at Fisher Scientific, Thermo Fisher and Beckman Coulter. She holds a B.A in Broadcast Journalism and Public Speaking from the University of Houston.

Dena Marrinucci Ph.D.

Co-Founder and Senior Vice President of Corporate Development and Business Operations

Dr. Marrinucci is a life science entrepreneur with a passion for introducing diagnostic technologies with potential to transform human health. She co-founded Truvian in late 2015 and leads research, operations, program management and strategic partnerships for the company. Prior to founding Truvian, Dr. Marrinucci founded Epic Sciences in 2008 and was the company’s Chief Scientific Officer. During her tenure at Epic, Dr. Marrinucci developed a novel circulating tumor cell technology and helped grow the company, overseeing its diagnostic collaborations with pharmaceutical companies and developing its clinical laboratory and assay development operations.

Dr. Marrinucci has been named to MIT Technology Review’s 35 Innovators Under 35, Foreign Policy’s Top 100 Leading Global Thinkers, and PharmaVoice 100’s Top Entrepreneurs. She was also named a 2016 Life Science Catalyst Award winner, has authored dozens of peer reviewed publications and is an inventor on 12 patents. Dr. Marrinucci also serves as an Advisor for Lynx Biosciences, a cancer diagnostic company. She holds a B.S. in Chemistry from the University of Vermont and a Ph.D. in Chemical Biology from The Scripps Research Institute.

Tho Tran

Vice President of Quality and Regulatory Affairs

Mr. Tran brings Truvian extensive experience in the medical device and diagnostics space, where he specializes in quality management and regulatory compliance. Throughout his career, he has orchestrated a variety of successful regulatory submissions and audits with the FDA, Health Canada, European Commission and other quality governing bodies worldwide. At Truvian, he is instrumental in the company’s plans toward securing FDA 510(k) clearance. Mr. Tran’s career in quality assurance includes his role as Director of Quality at GenMark Diagnostics, a leading provider of automated, multiplex molecular diagnostic testing systems. He has also held engineering roles with Life Technologies, Flextronics Medical, and Abbott Laboratories, where he was recognized with a management award for his leadership in implementing a new quality system and ProChain Project Management approach. Mr. Tran holds a B.S. from the School of Health Sciences at Excelsior College.

Board of Directors

Kim Kamdar, Ph.D.

Jeff Hawkins

Ashok Krishnamurthi

Paul Meister

Jean-Pierre "JP" Millon

Dr. Kamdar is a Partner with Domain Associates, a healthcare venture capital leader. With a background in small molecule drug discovery, she has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine. Dr. Kamdar is currently Chair of the Board of Directors of Obalon Therapeutics and serves on the boards of Epic Sciences, Evofem Biosciences, Omniome and Sera Prognostics. She is also a board member of San Diego’s CONNECT Foundation and an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine.

Dr. Kamdar is the author of 10 papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in Biochemistry and Genetics from Emory University.

For almost 20 years, Mr. Hawkins has held executive and management roles at the world’s leading healthcare companies. Specializing in the advancement of life-changing technologies, Mr. Hawkins joined Truvian Sciences as President and Chief Executive Officer in January 2018. Prior to Truvian, Mr. Hawkins was Vice President and General Manager of the Reproductive and Genetic Health Business at Illumina, Inc. Before Illumina, he served as Senior Vice President of Global Marketing and Program Management for GenMark Diagnostics. Previously, Mr. Hawkins held roles of increasing responsibility in business development for Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an M.B.A. from Keller Graduate School of Management.

Mr. Krishnamurthi is Managing Partner at Greatpoint Ventures, a California-based venture capital firm. A serial entrepreneur and investor, Mr. Krishnamurthi is focused on enterprise IT, and the intersection of computer science and life sciences. He founded two medical related companies – CAPP Medical, a liquid biopsy company for cancer diagnosis (sold to Roche Diagnostics), and CiberMed which focuses on biomarker discovery. He is currently a Board member of Activ Surgical, EVEN Financial, Insight-rx, Namogoo, Recogni and Scoredata.

Mr. Krishnamurthi has a B.S. in Electrical Engineering from Manipal Institute of Technology and a M.S. in Computer Engineering from Syracuse University.

Mr. Meister brings over three decades of experience to Truvian’s board, serving in senior executive and board roles for high-growth and publicly traded companies. Most recently, Mr. Meister served as President of MacAndrews & Forbes Incorporated, a private company that owns or controls a diverse set of companies, including Revlon, Scientific Games, Harlan Clarke Corp., and SIGA Technologies. Prior to that role, he was Chairman and CEO of inVentiv Health (now Syneos Health) and Chairman of the Board at Thermo Fisher Scientific. Mr. Meister co-founded Liberty Lane Partners, LLC, a private investment company and Perspecta Trust, a trust company that provides trust and investment services. He is currently Director of the boards at Arbor Biotechnologies, Inc., Core & Main LP, Magnolia Medical Technologies, Inc., PharmaLegacy Laboratories (Shanghai) Co., Ltd., Quanterix Corporation, Revlon, Inc., Scientific Games Corporation and Wheelabrator Technologies Holdings Inc., as well as Vice Chairman at The General Chemical Group.

Mr. Meister holds a B.A. from the University of Michigan and a M.B.A from Northwestern University’s Kellogg School of Management.

Mr. Millon brings decades of experience, expertise and leadership in the healthcare and life science industries to Truvian’s board. He is currently a director at CVS Health, Inc., a role to which he was appointed in 2007 and one that has evolved as a result of the CVS merger with Caremark in April 2007 and Caremark’s purchase of AdvancePCS, a pharmacy benefit management company, in March 2004. Before his post with Caremark, Millon was named to the board of AdvancePCS in 2000 upon the merger of Advance Paradigm and PCS Health Systems. Prior to that, he was president and chief executive officer of PCS from 1996 to 2000, and also served as an executive and held several global leadership positions over the span of two decades with Eli Lilly and Company.
Millon serves on a number of healthcare company boards, including InanoBio Inc., Curemetrix, Equality Health and Valenz, and is also on the advisory boards of several companies, including Sky Republic, Kazuhm and Curematch. The latter two are incubated by Analytics Ventures, where he is also an advisor.
Millon earned a degree in mechanical engineering from Ecole Centrale de Lyon, France, and a degree in economics from the University of Lyon, France. He was awarded a Master’s of Business Administration in finance from the Kellogg School of Management at Northwestern University. He is a trustee of Scottsdale Arts and a board member of ASU Biodesign Institute.

Kim Kamdar, Ph.D.

Dr. Kamdar is a Partner with Domain Associates, a healthcare venture capital leader. With a background in small molecule drug discovery, she has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine. Dr. Kamdar is currently Chair of the Board of Directors of Obalon Therapeutics and serves on the boards of Epic Sciences, Evofem Biosciences, Omniome and Sera Prognostics. She is also a board member of San Diego’s CONNECT Foundation and an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine.

Dr. Kamdar is the author of 10 papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in Biochemistry and Genetics from Emory University.

Jeff Hawkins

For almost 20 years, Mr. Hawkins has held executive and management roles at the world’s leading healthcare companies. Specializing in the advancement of life-changing technologies, Mr. Hawkins joined Truvian Sciences as President and Chief Executive Officer in January 2018. Prior to Truvian, Mr. Hawkins was Vice President and General Manager of the Reproductive and Genetic Health Business at Illumina, Inc. Before Illumina, he served as Senior Vice President of Global Marketing and Program Management for GenMark Diagnostics. Previously, Mr. Hawkins held roles of increasing responsibility in business development for Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an M.B.A. from Keller Graduate School of Management.

Ashok Krishnamurthi

Mr. Krishnamurthi is Managing Partner at Greatpoint Ventures, a California-based venture capital firm. A serial entrepreneur and investor, Mr. Krishnamurthi is focused on enterprise IT, and the intersection of computer science and life sciences. He founded two medical related companies – CAPP Medical, a liquid biopsy company for cancer diagnosis (sold to Roche Diagnostics), and CiberMed which focuses on biomarker discovery. He is currently a Board member of Activ Surgical, EVEN Financial, Insight-rx, Namogoo, Recogni and Scoredata.

Mr. Krishnamurthi has a B.S. in Electrical Engineering from Manipal Institute of Technology and a M.S. in Computer Engineering from Syracuse University.

Paul Meister

Mr. Meister brings over three decades of experience to Truvian’s board, serving in senior executive and board roles for high-growth and publicly traded companies. Most recently, Mr. Meister served as President of MacAndrews & Forbes Incorporated, a private company that owns or controls a diverse set of companies, including Revlon, Scientific Games, Harlan Clarke Corp., and SIGA Technologies. Prior to that role, he was Chairman and CEO of inVentiv Health (now Syneos Health) and Chairman of the Board at Thermo Fisher Scientific. Mr. Meister co-founded Liberty Lane Partners, LLC, a private investment company and Perspecta Trust, a trust company that provides trust and investment services. He is currently Director of the boards at Arbor Biotechnologies, Inc., Core & Main LP, Magnolia Medical Technologies, Inc., PharmaLegacy Laboratories (Shanghai) Co., Ltd., Quanterix Corporation, Revlon, Inc., Scientific Games Corporation and Wheelabrator Technologies Holdings Inc., as well as Vice Chairman at The General Chemical Group.

Mr. Meister holds a B.A. from the University of Michigan and a M.B.A from Northwestern University’s Kellogg School of Management.

Jean-Pierre "JP" Millon

Mr. Millon brings decades of experience, expertise and leadership in the healthcare and life science industries to Truvian’s board. He is currently a director at CVS Health, Inc., a role to which he was appointed in 2007 and one that has evolved as a result of the CVS merger with Caremark in April 2007 and Caremark’s purchase of AdvancePCS, a pharmacy benefit management company, in March 2004. Before his post with Caremark, Millon was named to the board of AdvancePCS in 2000 upon the merger of Advance Paradigm and PCS Health Systems. Prior to that, he was president and chief executive officer of PCS from 1996 to 2000, and also served as an executive and held several global leadership positions over the span of two decades with Eli Lilly and Company.
Millon serves on a number of healthcare company boards, including InanoBio Inc., Curemetrix, Equality Health and Valenz, and is also on the advisory boards of several companies, including Sky Republic, Kazuhm and Curematch. The latter two are incubated by Analytics Ventures, where he is also an advisor.
Millon earned a degree in mechanical engineering from Ecole Centrale de Lyon, France, and a degree in economics from the University of Lyon, France. He was awarded a Master’s of Business Administration in finance from the Kellogg School of Management at Northwestern University. He is a trustee of Scottsdale Arts and a board member of ASU Biodesign Institute.